These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 38699983)

  • 1. A comparative analysis of kidney allograft outcomes in steroid use versus steroid discontinuation after basiliximab and ATG induction: A UNOS database study.
    Nissaisorakarn P; Patel H; Cardarelli F; Amtul A
    Clin Nephrol; 2024 Jul; 102():39-50. PubMed ID: 38699983
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-Dose Thymoglobulin versus Basiliximab Induction Therapy in Low-Risk Living Related Kidney Transplant Recipients: Three-Year Follow-Up Study.
    Martinez-Mier G; Moreno-Ley PI; Budar-Fernández LF; Méndez-López MT; Allende-Castellanos CA; Jiménez-López LA; Barrera-Amoros DA; Reyes-Ruiz JM
    Arch Med Res; 2024 Sep; 55(6):103047. PubMed ID: 39079480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Steroid maintenance in repeat kidney transplantation: influence of induction agents on outcomes.
    Sureshkumar KK; Hussain SM; Nashar K; Marcus RJ
    Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):741-9. PubMed ID: 24969182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A retrospective comparison of the efficacy and safety in kidney transplant recipients with basiliximab and anti-thymocyte globulin.
    Wang W; Yin H; Li XB; Hu XP; Yang XY; Liu H; Ren L; Wang Y; Zhang XD
    Chin Med J (Engl); 2012 Mar; 125(6):1135-40. PubMed ID: 22613543
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome.
    Kesiraju S; Paritala P; Rao Ch UM; Athmakuri SM; Reddy VS; Sahariah S
    Saudi J Kidney Dis Transpl; 2014 Jan; 25(1):9-15. PubMed ID: 24434376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymoglobulin versus basiliximab induction therapy for simultaneous kidney-pancreas transplantation: impact on rejection, graft function, and long-term outcome.
    Bazerbachi F; Selzner M; Boehnert MU; Marquez MA; Norgate A; McGilvray ID; Schiff J; Cattral MS
    Transplantation; 2011 Nov; 92(9):1039-43. PubMed ID: 22002345
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction treatment with rabbit antithymocyte globulin versus basiliximab in renal transplant recipients with planned early steroid withdrawal.
    Martin ST; Roberts KL; Malek SK; Tullius SG; Vadivel N; De Serres S; Grafals M; Elsanjak A; Filkins BA; Chandraker A; Gabardi S
    Pharmacotherapy; 2011 Jun; 31(6):566-73. PubMed ID: 21923440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of single-dose anti-thymocyte globulin versus basiliximab induction therapy in pediatric kidney transplant recipients: A retrospective comparative cohort study.
    Custodio LFP; Martins SBS; Viana LA; Cristelli MP; Requião-Moura L; Chow CYZ; Camargo SFDN; Nakamura MR; Foresto RD; Tedesco-Silva H; Medina-Pestana J
    Pediatr Transplant; 2024 May; 28(3):e14713. PubMed ID: 38553819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of basiliximab vs antithymocyte globulin for induction in pediatric heart transplant recipients: An analysis of the International Society for Heart and Lung Transplantation database.
    Butts RJ; Dipchand AI; Sutcliffe D; Bano M; Dimas V; Morrow R; Das B; Kirk R
    Pediatr Transplant; 2018 Jun; 22(4):e13190. PubMed ID: 29878688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection.
    Sollinger H; Kaplan B; Pescovitz MD; Philosophe B; Roza A; Brayman K; Somberg K
    Transplantation; 2001 Dec; 72(12):1915-9. PubMed ID: 11773888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes of Early Steroid Withdrawal in Recipients of Deceased-Donor Expanded Criteria Kidney Transplants in the Era of Induction Therapy.
    Hussain SM; Marcus RJ; Ko TY; Nashar K; Thai NL; Sureshkumar KK
    Exp Clin Transplant; 2016 Jun; 14(3):287-93. PubMed ID: 27221720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rabbit antithymocyte globulin compared with basiliximab in kidney transplantation: a single-center study.
    Kim JM; Jang HR; Kwon CH; Huh WS; Kim GS; Kim SJ; Joh JW; Oh HY
    Transplant Proc; 2012 Jan; 44(1):167-70. PubMed ID: 22310606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction Therapies in Live Donor Kidney Transplantation on Tacrolimus and Mycophenolate With or Without Steroid Maintenance.
    Tanriover B; Zhang S; MacConmara M; Gao A; Sandikci B; Ayvaci MU; Mete M; Tsapepas D; Rajora N; Mohan P; Lakhia R; Lu CY; Vazquez M
    Clin J Am Soc Nephrol; 2015 Jun; 10(6):1041-9. PubMed ID: 25979971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low-dose rabbit anti-thymoglobin globulin versus basiliximab for induction therapy in kidney transplantation.
    Patel HV; Kute VB; Vanikar AV; Shah PR; Gumber MR; Engineer DP; Trivedi HL
    Saudi J Kidney Dis Transpl; 2014 Jul; 25(4):819-22. PubMed ID: 24969194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating anti-thymocyte globulin induction doses for better allograft and patient survival in Asian kidney transplant recipients.
    Shim YE; Ko Y; Lee JP; Jeon JS; Jun H; Yang J; Kim MS; Lim SJ; Kwon HE; Jung JH; Kwon H; Kim YH; Lee J; Shin S;
    Sci Rep; 2023 Aug; 13(1):12560. PubMed ID: 37532735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alemtuzumab induction is associated with decreased hospitalization rates in pediatric kidney transplant: A UNOS data review for safety and outcomes with common induction regimens.
    Aydin-Ghormoz E; Ortiz J; Koizumi N; Li MH; Faddoul G
    Pediatr Transplant; 2024 Jun; 28(4):e14783. PubMed ID: 38767019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute Rejection Rates and Graft Outcomes According to Induction Regimen among Recipients of Kidneys from Deceased Donors Treated with Tacrolimus and Mycophenolate.
    Tanriover B; Jaikaransingh V; MacConmara MP; Parekh JR; Levea SL; Ariyamuthu VK; Zhang S; Gao A; Ayvaci MUS; Sandikci B; Rajora N; Ahmed V; Lu CY; Mohan S; Vazquez MA
    Clin J Am Soc Nephrol; 2016 Sep; 11(9):1650-1661. PubMed ID: 27364616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy.
    Mattei MF; Redonnet M; Gandjbakhch I; Bandini AM; Billes A; Epailly E; Guillemain R; Lelong B; Pol A; Treilhaud M; Vermes E; Dorent R; Lemay D; Blanc AS; Boissonnat P
    J Heart Lung Transplant; 2007 Jul; 26(7):693-9. PubMed ID: 17613399
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.